NCT00117312 - Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions

Prostate Cancer

Interventions

DRUG

Degarelix

One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.

DRUG

Degarelix

One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.

DRUG

Degarelix

One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.

DRUG

Degarelix

One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.

Trial Locations (12)

20770

Drs. Werner, Murdock & Francis, PA, Greenbelt

33710

Pinellas Urology, Inc., St. Petersburg

33907

SW Florida Urological Associates, Fort Myers

74104

Urology Specialists of Oklahoma, Inc., Tulsa

75231

Urology Clinics of NorthTexas, PA, Dallas

78229

Urology San Antonio Research, San Antonio

80210

Urology Associate PC', Denver

89511

Nevada Urology Associates, Reno

90505

Western Clinical Research, Torrance

92404

San Bernardino Urological Associates Medical Group, San Bernardino

92653

South Orange County Medical Research Center, Laguna Woods

92801

Advanced Urology Medical Center, Anaheim